Eli Lilly and Novo Nordisk are, for now, the undisputed champions of the market for weight-loss medicines. Thanks to the outrageous popularity of Lilly's drug Zepbound and Novo's product Wegovy, the biggest contest of the moment will go to whoever can ramp up their manufacturing capacity the fastest, such that they can serve the market's overflowing demand.

But the market for weight-loss therapies could be as large as $100 billion by 2030, according to many estimates, so there's no way that these two juggernauts will be the only players making money for much longer. Lesser-known biotechs like Altimmune (NASDAQ: ALT) and Terns Pharmaceuticals (NASDAQ: TERN) could well make for great investments, and they don't even need to capture a very big market share to grow by a large proportion relative to where they are today.

With that in mind, let's analyze both companies to see if they might have what it takes to beat the leaders in the future.

Continue reading

Source Fool.com